Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).-论文-万方医学网

作者： Matthew J,Ellis ^[1] ; Vera J,Suman ^[1] ; Jeremy,Hoog ^[1] ; Rodrigo,Goncalves ^[1] ; Souzan,Sanati ^[1] ; Chad J,Creighton ^[1] ; Katherine,DeSchryver ^[1] ; Erika,Crouch ^[1] ; Amy,Brink ^[1] ; Mark,Watson ^[1] ; Jingqin,Luo ^[1] ; Yu,Tao ^[1] ; Michael,Barnes ^[1] ; Mitchell,Dowsett ^[1] ; G Thomas,Budd ^[1] ; Eric,Winer ^[1] ; Paula,Silverman ^[1] ; Laura,Esserman ^[1] ; Lisa,Carey ^[1] ; Cynthia X,Ma ^[1] ; Gary,Unzeitig ^[1] ; Timothy,Pluard ^[1] ; Pat,Whitworth ^[1] ; Gildy,Babiera ^[1] ; J Michael,Guenther ^[1] ; Zoneddy,Dayao ^[1] ; David,Ota ^[1] ; Marilyn,Leitch ^[1] ; John A,Olson ^[1] ; D Craig,Allred ^[1] ; Kelly,Hunt ^[1]

作者单位： Matthew J. Ellis and Chad J. Creighton, Baylor College of Medicine; Gildy Babiera and Kelly Hunt, MD Anderson Cancer Center, Houston; Gary Unzeitig, Doctor's Hospital of Laredo, Laredo; Marilyn Leitch, University of Texas Southwestern Campus, Dallas, TX; Vera J. Suman, Mayo Clinic, Rochester MN; Jeremy Hoog, Rodrigo Goncalves, Souzan Sanati, Katherine DeSchryver, Erika Crouch, Amy Brink, Mark Watson, Jingqin Luo, Yu Tao, Cynthia X. Ma, and D. Craig Allred, Washington University School of Medicine, St Louis; Timothy Pluard, St Lukes Hospital, Kansas City, MO; Michael Barnes, Roche Diagnostics, Mountain View; Laura Esserman, University of California San Francisco, San Francisco, CA; Mitchell Dowsett, Royal Marsden Hospital, London, UK; G. Thomas Budd, Cleveland Clinic; Paula Silverman, Case Western Reserve University, Cleveland OH; Eric Winer, Dana-Farber Cancer Institute, Boston MA; Lisa Carey, University of North Carolina, Chapel Hill; David Ota, Duke University, Durham, NC; Pat Whitworth, Nashville Breast Center, Nashville, TN; J. Michael Guenther, St Elizabeth Medical Center, Edgewood, KY; Zoneddy Dayao, University of New Mexico, Albuquerque, NM; and John A. Olson Jr, University of Maryland School of Medicine and Greenebaum Cancer Center, Baltimore, MD. ^[1]

主题词老年人(Aged);雄二烯类(Androstadienes);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);芳香酶抑制剂(Aromatase Inhibitors);乳腺肿瘤(Breast Neoplasms);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);Ki-67抗原(Ki-67 Antigen);中年人(Middle Aged);有丝分裂指数(Mitotic Index);肿瘤辅助疗法(Neoadjuvant Therapy);肿瘤转移(Neoplasm Metastasis);肿瘤复发, 局部(Neoplasm Recurrence, Local);肿瘤分期(Neoplasm Staging);腈类(Nitriles);试验预期值(Predictive Value of Tests);预后(Prognosis);比例危险度模型(Proportional Hazards Models);受体, 雌激素(Receptors, Estrogen);受体, 孕酮(Receptors, Progesterone);存活率(Survival Rate);三唑类(Triazoles)

DOI 10.1200/JCO.2016.69.4406

PMID 28045625

发布时间 2022-11-09

检索历史清除

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

Journal of clinical oncology

相似文献

Journal of clinical oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

Journal of clinical oncology

相似文献

Journal of clinical oncology

相关期刊

检索历史清除